Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

821
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
821
Drug Product Performance: In Vitro–In Vivo Correlation01:20

Drug Product Performance: In Vitro–In Vivo Correlation

336
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
336
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

58
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
58
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

50
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
50
Prediction Intervals01:03

Prediction Intervals

3.5K
The interval estimate of any variable is known as the prediction interval. It helps decide if a point estimate is dependable.
However, the point estimate is most likely not the exact value of the population parameter, but close to it. After calculating point estimates, we construct interval estimates, called confidence intervals or prediction intervals. This prediction interval comprises a range of values unlike the point estimate and is a better predictor of the observed sample value, y. 
3.5K
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

301
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
301

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sleeve gastrectomy versus roux-en-Y gastric bypass for remission of type 2 diabetes mellitus and obesity: systematic review and meta-analysis of randomized controlled trials.

International journal of surgery (London, England)·2025
Same author

Effect of nonsurgical periodontal therapy on coronary artery disease or metabolic syndrome: a systematic review and meta-analysis.

The journal of evidence-based dental practice·2025
Same author

Bioengineering Platelets Presenting PD-L1, Galectin-9 and BTLA to Ameliorate Type 1 Diabetes.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025
Same author

EML4-ALK-Positive Ovarian Cancer With Intracranial Metastasis Responds to Lorlatinib: A Case Report and Literature Review.

Clinical case reports·2025
Same author

Nesfatin-1 is involved in hyperbaric oxygen-mediated therapeutic effects in high fat diet-induced hyperphagia in mice.

Peptides·2024
Same author

Discovery of Novel <i>Neo</i>-Clerodane Derivatives as Potent Dual-Functional Antiosteoporosis Agents through Targeting Peroxisome Proliferator-Activated Receptor-γ.

Journal of medicinal chemistry·2024
Same journal

Repurposing bleomycin against Acinetobacter baumannii HisG: computational, biophysical, and antibacterial evidence.

Journal of computer-aided molecular design·2026
Same journal

Topological data analysis for antibody-drug conjugate payload discovery: a computational framework for mechanistic classification and target validation.

Journal of computer-aided molecular design·2026
Same journal

Commentary on the fundamentals and development of artificial intelligence models in the life sciences and best research practices.

Journal of computer-aided molecular design·2026
Same journal

RANQSAR: a standalone open-source application for reproducible machine learning-based QSAR analysis.

Journal of computer-aided molecular design·2026
Same journal

Integrating evolutionary and compositional features with ML and DL for robust and interpretable druggable protein prediction.

Journal of computer-aided molecular design·2026
Same journal

QUAD: a composite risk framework integrating uncertainty, applicability domain, and model disagreement for reliable QSAR predictions.

Journal of computer-aided molecular design·2026
See all related articles

Related Experiment Video

Updated: Mar 8, 2026

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.9K

Predicting DPP-IV inhibitors with machine learning approaches.

Jie Cai1, Chanjuan Li1, Zhihong Liu1

  • 1Research Center for Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, 132 East Circle at University City, Guangzhou, 510006, China.

Journal of Computer-Aided Molecular Design
|February 4, 2017
PubMed
Summary
This summary is machine-generated.

Machine learning models predict novel dipeptidyl peptidase IV (DPP-IV) inhibitors for Type 2 diabetes mellitus. These models identify beneficial and detrimental structural fragments, aiding in the design of safer diabetes medications with fewer side effects.

Keywords:
CheminformaticsDPP-IVNaïve Bayesian learningRecursive partitioningVirtual screening

Related Experiment Videos

Last Updated: Mar 8, 2026

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.9K

Area of Science:

  • Medicinal Chemistry
  • Computational Chemistry
  • Pharmacology

Background:

  • Dipeptidyl peptidase IV (DPP-IV) inhibitors are crucial for managing Type 2 Diabetes Mellitus (T2DM) by enhancing incretin hormone action.
  • Current DPP-IV inhibitors exhibit limitations, including adverse effects and structural diversity hindering conventional quantitative structure-activity relationship (QSAR) modeling.
  • There is a significant need for novel DPP-IV inhibitors with improved safety profiles and effective virtual screening strategies.

Purpose of the Study:

  • To develop advanced machine learning models for predicting novel DPP-IV inhibitors.
  • To overcome limitations of traditional QSAR approaches due to the structural diversity of existing DPP-IV inhibitors.
  • To identify key structural fragments that contribute to or detract from DPP-IV inhibitory activity.

Main Methods:

  • Utilized machine learning approaches, specifically Naïve Bayesian (NB) and Recursive Partitioning (RP) methods.
  • Developed 247 predictive models using 1307 known DPP-IV inhibitors, employing optimized molecular properties and topological fingerprints as descriptors.
  • Validated model performance using an external test set of 65 compounds, assessing predictive accuracy.

Main Results:

  • Achieved overall predictive accuracies exceeding 80% for the developed machine learning models.
  • Demonstrated good predictive ability for both NB and RP models across various descriptor combinations.
  • Successfully derived 20 beneficial and 20 detrimental structural fragments for DPP-IV inhibitors.

Conclusions:

  • Machine learning, particularly NB and RP methods, offers a robust strategy for predicting DPP-IV inhibitors.
  • The developed models provide valuable insights into structure-activity relationships, aiding in the design of next-generation T2DM therapeutics.
  • Identification of key structural fragments can guide the rational design of novel DPP-IV inhibitor scaffolds with enhanced efficacy and safety.